Regeneration: GHRP-2 (Growth Hormone Releasing Peptide — Ghrelin Receptor Agonist)

A synthetic peptide that harnesses the ghrelin receptor to drive pulsatile GH release — from diagnostics to muscle protection

GHRP-2 (Growth Hormone Releasing Peptide-2, also known as Pralmorelin, KP-102 D / KP-102 LN) is a synthetic hexapeptide that acts as a selective agonist at the ghrelin receptor (GHS-R1a) and stimulates the pulsatile release of growth hormone (GH) from the anterior pituitary. Developed by Dr. Cyril Bowers at Tulane University, GHRP-2 was one of the first growth hormone secretagogues to be systematically studied in humans. Unlike exogenous recombinant GH, the GH release stimulated by GHRP-2 remains subject to physiological negative feedback control by somatostatin and IGF-I, making supra-therapeutic levels less likely. This review summarizes the mechanism of action, clinical applications, metabolic effects, muscle-protective properties, and safety profile based on 12 PubMed-referenced studies.

Mechanism: How GHRP-2 Works

Ghrelin Receptor (GHS-R1a) Agonism

The molecular target of GHRP-2 is the Growth Hormone Secretagogue Receptor 1a (GHS-R1a), which was cloned in 1996 and later identified as the natural ghrelin receptor. GHS-R1a is a G-protein-coupled receptor (GPCR) that activates phospholipase C (PLC) via Gq/11 proteins, leading to the production of IP₃ and DAG. The resulting increase in intracellular calcium concentration in somatotrope cells of the anterior pituitary is the primary signaling pathway that triggers the exocytosis of GH storage granules.

This mechanism is fundamentally different from that of endogenous Growth Hormone-Releasing Hormone (GHRH), which acts via a Gs-coupled receptor and activates the cAMP/PKA axis. GHRP-2 and GHRH utilize different second messenger systems, which makes their combined administration synergistic — the basis for the "triple test" (GHRH + GHRP-2 + arginine) as the most sensitive stimulation test for GH deficiency.

GHS-R1a is expressed not only in the pituitary but also in the hypothalamus, hippocampus, stomach, pancreas, and cardiovascular system. This broad expression explains the pleiotropic effects of GHRP-2 — from appetite stimulation to cardioprotective actions to modulation of glucose homeostasis.

The review by Ghigo et al. (PMID 9186261) in the European Journal of Endocrinology (1997) summarizes the early GHRP research: The GHRPs have no structural homology with GHRH and act via specific, independent receptors. The GHRP receptor showed no sequence homology with other known GPCRs — which strongly suggested a natural, yet-undiscovered ligand (postulated as the "U-factor" until ghrelin was identified in 1999).

Pulsatile GH Release and Feedback Control

One of the most important features of GHRP-2's action is the maintenance of the pulsatile nature of GH secretion. GH is physiologically released in pulses — with peaks approximately every 3–4 hours and the greatest amplitudes during the first hours of deep sleep. This pulsatility is functionally significant: different pulse amplitudes activate differential signaling pathways (JAK-STAT vs. MAPK) with differential effects on IGF-I, lipolysis, and glucose homeostasis.

In contrast to exogenous rhGH, which produces a supraphysiological, non-pulsatile GH level, GHRP-2 stimulates the body's own pulsatile GH production, which remains subject to feedback control by somatostatin and IGF-I. This is the central pharmacological advantage of all GH secretagogues: the risk of supra-therapeutic levels and associated side effects (insulin resistance, edema, arthralgia) is reduced by intact feedback regulation.

The review by Sigalos & Pastuszak (PMID 28400207) emphasizes precisely this: "GHSs promote pulsatile release of GH that is subject to negative feedback and can prevent supra-therapeutic levels of GH and their sequelae." This makes GH secretagogues like GHRP-2 theoretically more attractive than recombinant GH for applications where physiological GH restitution is desired — such as in age-associated GH deficiency or in recovery from catabolic events.

Synergy with GHRH and Other Interactions

The GH-releasing effect of GHRP-2 is synergistic with that of GHRH, not merely additive. This means that the combined administration of GHRH + GHRP-2 produces a GH response that far exceeds the sum of the individual doses. This synergy is the basis for the use of GHRP-2 in combined stimulation tests, which demonstrate higher sensitivity than single-agent tests.

The action of GHRP-2 is also subject to inhibitory influences: somatostatin, high-dose glucose, free fatty acids, glucocorticoids, and exogenous rhGH can reduce the GH response — systematically summarized in the review by Camanni et al. (PMID 9465289) in Frontiers in Neuroendocrinology (1998). For clinical interpretation, this is important: a falsely low GH response can be caused by hyperglycemia, obesity-related somatostatin elevation, or glucocorticoid administration.

The review by Argente et al. (PMID 8950613) in Hormone Research (1996) further demonstrated that GHRP-2 is orally active — after oral administration, GH levels rose in healthy children starting at 15 minutes, with a peak at 60 minutes. This oral activity was a key finding that motivated pharmaceutical interest in GHRPs as oral alternatives to injectable rhGH.

Clinical Applications

GH Deficiency Diagnostics in Adults

The GHRP-2 stimulation test has been established as a safe and reliable method for diagnosing Growth Hormone Deficiency (GHD) in adults. Suzuki et al. (PMID 35795807) in the Journal of the Endocrine Society (2022) investigated 36 patients with hypothalamic-pituitary disorders and compared the GHRP-2 test with the cosyntropin, CRH, and insulin tolerance test (ITT):

• GH Deficiency Prevalence: 61% of patients had severe GHD, 8% had moderate GHD — the GHRP-2 test correlated significantly with the reference tests
• Surprising ACTH Effect: GHRP-2 stimulated not only GH but also ACTH — and this ACTH rise correlated with the presence of secondary adrenal insufficiency (AI). Of the 17 patients (47%) with secondary AI, 16 (94%) simultaneously had severe GHD
• Diagnostic Value: ROC analysis yielded an ACTH cut-off of 1.55-fold above baseline (83% sensitivity, 88% specificity) for screening for pituitary AI. The combination of ACTH rise and peak cortisol (cut-off 10 µg/dL) achieved a specificity of 100% with an accuracy of 0.94

The authors recommended measuring ACTH in addition to GH during the GHRP-2 test to avoid missing a concomitant secondary adrenal insufficiency — clinically highly relevant, as untreated AI can be life-threatening. This makes the GHRP-2 test a combined hypothalamic-pituitary screening instrument.

GH Deficiency Diagnostics in Children

Asakura et al. (PMID 20662346) in J Pediatr Endocrinol Metab (2010) validated the GHRP-2 test in 56 children with growth disorders (2 µg/kg i.v.) and compared it with the ITT:

• Correlation with ITT: The Spearman correlation coefficient for GH peak values between the GHRP-2 test and ITT was significant (p < 0.0001), confirming the equivalence of the tests
• Diagnostic Cut-off: A GH peak of 15 µg/L (ng/mL) was identified as the cut-off — the point at which sensitivity and specificity intersect
• Significant Differentiation: Children with GHD had a median GH peak of 3.39 µg/L vs. 25.10 µg/L in children without GHD (p < 0.0001)
• Practical Advantages: The GHRP-2 test was safe, took less than one hour, and was feasible in children for whom the ITT is contraindicated (e.g., seizure disorders, cardiovascular disease)

The ITT is considered the gold standard but is contraindicated in children under 5 years, in seizure disorders, and in cardiovascular risk — and requires strict monitoring due to the risk of hypoglycemia. The GHRP-2 test offers a safe, rapidly feasible, and age-independent alternative without hypoglycemia risk.

Diagnostics of TSH-Producing Pituitary Adenomas

Kageyama et al. (PMID 29973439) in Endocrine Journal (2018) described a further diagnostic application: TSH-producing pituitary adenomas (TSHom) — a rare cause of hyperthyroidism.

The rationale: GHRP-2 induces no TSH secretion in healthy individuals. In TSHom patients, the tumor may respond with TSH release. The study investigated 5 patients with GHRP-2, TRH, octreotide, and bromocriptine tests:

• 40% of patients showed a significant TSH response to GHRP-2 (>50% rise above baseline); one additional patient showed a 48% rise
• Postoperative Course: In one patient with complete adenoma resection, basal TSH levels suppressed adequately postoperatively, and GHRP-2 no longer stimulated a TSH rise — confirming the tumor specificity of the response
• TRH Test: 80% of patients showed a weak TSH response to TRH — the GHRP-2 test was thus at least equally informative

Although the case number is small, this study suggests that the GHRP-2 test may be useful as a supplementary diagnostic instrument in the differential diagnosis of TSHom.

Drug Review: Pralmorelin as a Pharmaceutical Development

The drug review article (PMID 15230633) in Drugs in R&D (2004) summarizes the pharmaceutical development. Pralmorelin was developed as an orally active, synthetic GHRP from 3–5 amino acid peptides. Key findings:

• Diagnostic Efficacy: Pralmorelin increases GH in healthy individuals independently of sex, obesity, or age. In GH-deficient patients, the effect is significantly smaller — which establishes its diagnostic utility
• ROC Analysis: A GH peak cut-off of 15.0 µg/L distinguished GH-deficient patients from healthy individuals — later confirmed in the pediatric study (PMID 20662346)
• Licensing: Kaken (Japan) acquired worldwide rights; Wyeth licensed for the US/Canada. In Japan, Pralmorelin was approved as a diagnostic agent for hypothalamic-pituitary function

In Europe, GHRP-2 never received approval — due to commercial and regulatory factors (Wyeth/Merck prioritized MK-0677/Ibutamoren).

Metabolic Effects

Appetite Stimulation: GHRP-2 as a Ghrelin Mimetic

One of the most fascinating effects of GHRP-2 outside of GH stimulation is appetite stimulation — an effect that directly results from agonist activity at the ghrelin receptor. Ghrelin is the most potent known orexigenic (appetite-stimulating) hormone in the human body, and GHRP-2 as a synthetic ghrelin agonist reproduces this effect pharmacologically.

The landmark study on this was published by Laferrère et al. (PMID 15699539) in the Journal of Clinical Endocrinology & Metabolism (2005). Seven lean, healthy men received either GHRP-2 (1 µg/kg/h subcutaneously over 270 minutes) or saline, followed by an ad libitum buffet meal:

• Food Intake: Under GHRP-2, subjects ate 35.9 ± 10.9% more than under placebo — and every single subject increased their intake, also adjusted for body weight (32.5 ± 3.1 kcal/kg vs. 24.2 ± 2.5 kcal/kg, p = 0.008)
• Macronutrient Composition: No difference in the percentage distribution of carbohydrates, fats, and proteins — GHRP-2 thus increased total caloric intake, not the preference for specific nutrients
• GH Levels: As expected, GH levels rose significantly (AUC 5550 ± 1090 µg/L/240 min vs. 412 ± 161 µg/L/240 min, p = 0.003)

This study was the first demonstration in humans that GHRP-2, like ghrelin, increases food intake — potentially useful in cachexia, potentially undesirable in weight-loss goals.

Visceral Adiposity and IGF-I: Predictors of GHRP-2 Efficacy

The efficacy of GHRP-2 as a GH secretagogue is modulated by body composition and hormonal status. Iranmanesh et al. (PMID 19351723) in JCEM (2009) investigated 13 young (23 ± 1.1 yr) and 12 older men (57 ± 1.7 yr) under a GnRH agonist-induced hypogonadal clamp (eliminating sex steroid influence) with GHRH and GHRP-2 stimulation:

• Age Effect: Even under hypogonadal conditions, older men had 6.8-fold lower pulsatile GH secretion (p < 0.001) and 2-fold lower maximal GH responses to both GHRH (p = 0.0065) and GHRP-2 (p = 0.022)
• Visceral Fat as Negative Predictor: Abdominal visceral fat mass (measured by CT) was the dominant negative predictor for both GHRH (R² = 0.49; p = 0.001) and GHRP-2 efficacy (R² = 0.38; p = 0.005)
• IGF-I as Positive Predictor: Fasting IGF-I levels correlated positively with GHRH (R² = 0.52; p < 0.001) and GHRP-2 efficacy (R² = 0.31; p = 0.018)

The clinical significance: Visceral adiposity directly suppresses the GH reserve — independent of age and sex hormone status. In obese patients, the GHRP-2 test may yield false-positive results for GHD. Low IGF-I also correlates with poorer GHRP-2 response and reflects reduced pituitary sensitivity.

Cortisol Response and Secretagogue-Specific Effects

A randomized, double-blind, placebo-controlled study by Iranmanesh et al. (PMID 20299490) in the European Journal of Endocrinology (2010) investigated the cortisol response to various GH secretagogues under different sex steroid milieus. Forty-two healthy men received a 4-arm design of placebo, testosterone, testosterone + dutasteride, or testosterone + anastrozole, and were tested with saline, GHRH, GHRP-2, somatostatin, or GHRP-2/GHRH/arginine (triple stimulus):

• Secretagogue-Specific Cortisol Response: The stimulated peak cortisol concentration was strongly dependent on secretagogue type (p < 0.001): triple stimulus (868 ± 27 nmol/L) > GHRP-2 (616 ± 42 nmol/L) > saline = somatostatin = GHRH (mean 420 ± 21 nmol/L)
• GHRP-2 and Age: After GHRP-2 injection, pulsatile cortisol secretion correlated positively with age (R² = 0.16, p = 0.012)
• Triple Stimulus and Visceral Fat: After the triple stimulus, pulsatile cortisol secretion correlated inversely with DHT levels (R² = 0.53, p = 0.026) and directly with visceral fat (R² = 0.11, p = 0.038)

GHRP-2 thus produces — in contrast to GHRH — a significant ACTH/cortisol stimulation that is associated with age and visceral adiposity. For the interpretation of stimulation tests, this is relevant: a cortisol rise during the GHRP-2 test is normal and not a sign of Cushing's syndrome.

Muscle Protection in Catabolic States

Burn Injury and Muscle Proteolysis

One of the most promising application areas for GHRP-2 is the protection of skeletal muscle in catabolic states. The most relevant study on this was published by Sheriff et al. (PMID 19577604) in Peptides (2009), investigating the effect of GHRP-2 on burn injury-induced muscle proteolysis in rats.

The study by Sheriff et al. showed that continuous GHRP-2 administration via a minipump (24 h in vivo release) had the following effects:

• Attenuation of IL-6 mRNA Expression: The IL-6 expression in skeletal muscle induced by the burn trauma was significantly reduced — an anti-inflammatory effect that interrupts the catabolic cascade upstream
• Suppression of E3 Ubiquitin Ligases: GHRP-2 attenuated the burn-induced increase in mRNA expression of MuRF-1 (Muscle RING-finger protein-1) and MAFbx (Muscle Atrophy F-box, also called Atrogin-1) — the two most important muscle-specific E3 ubiquitin ligases that catalyze the proteolytic degradation of myofibrillar protein
• Reduction of Proteolysis: The total and myofibrillar protein degradation rate in the extensor digitorum longus (EDL) muscle, elevated by the burn trauma, was significantly attenuated by GHRP-2

MuRF-1 and MAFbx are the "master switches" of muscular atrophy — they ubiquitinate specific substrates (MuRF-1: myosin heavy chain; MAFbx: eIF3-f) for proteasomal degradation. GHRP-2 blocks this primary atrophy mechanism at the transcriptional level. As a more stable hexapeptide (vs. 28-amino-acid ghrelin), GHRP-2 is of interest for potential intensive care applications. The IL-6-suppressive effect is mediated directly via the ghrelin receptor on macrophages (NF-κB inhibition).

Safety & Side Effects

General Safety Profile

The most comprehensive overview of the safety profile is provided by the review of Sigalos & Pastuszak (PMID 28400207) in Sex Medicine Reviews (2018), which systematically evaluates the literature on GH secretagogues in humans. Key statements on GHRP-2 and related substances:

• Feedback Control: GHSs promote pulsatile GH release under negative feedback by somatostatin and IGF-I — reduced risk of edema, arthralgia, and carpal tunnel syndrome vs. rhGH
• Primary Concern — Insulin Sensitivity: Blood glucose elevations due to decreased insulin sensitivity are the primary safety concern; chronic stimulation may impair glucose tolerance
• Positive Effects: Improved growth velocity in children, appetite stimulation and lean mass in wasting conditions, reduced bone turnover, improved sleep quality
• Tolerability: "GHSs are well tolerated" — good tolerability in available studies
• Research Needs: Long-term studies on cancer incidence and mortality are lacking

Specific Side Effects of GHRP-2

• Injection Site Reactions: Redness, swelling, mild pain — the most common side effect, self-limiting
• Appetite Stimulation: Increased food intake by ~36% (PMID 15699539) — undesirable in weight-loss goals, potentially useful in cachexia
• ACTH/Cortisol Stimulation: GHRP-2 stimulates ACTH and cortisol (PMID 20299490) — relevant in Cushing's syndrome or chronic administration
• Glucose Homeostasis: GH stimulation may worsen insulin sensitivity; the review warns of "increases in blood glucose because of decreases in insulin sensitivity" (PMID 28400207)
• Flushing & Drowsiness: Transient warmth sensation and somnolence after higher doses — mild and self-limiting

Contraindications and Precautions

• Active Malignancies: GH and IGF-I are mitogenic; GHRP-2 should not be used in patients with active tumors
• Diabetes Mellitus: Only with close glucose monitoring and adjustment of antidiabetic therapy
• Cushing's Syndrome: Contraindicated due to ACTH/cortisol stimulation
• Pregnancy and Lactation: No controlled data — do not use
• Children and Adolescents: Chronic therapeutic use only within controlled clinical trials

Comparison with Other GH Secretagogues

GHRP-2 is not the only GH secretagogue. The reviews by Ghigo et al. (PMID 9186261) and Camanni et al. (PMID 9465289) provide the best systematic overview of the GHRP family. The following comparison summarizes the key differences:

Sources: PMID 9186261 (Eur J Endocrinol, 1997), PMID 9465289 (Front Neuroendocrinol, 1998), PMID 28400207 (Sex Med Rev, 2018), PMID 15230633 (Drugs R D, 2004).

GHRP-2 vs. Sermorelin

Sermorelin (GHRH 1-29) acts via the GHRH receptor (Gs/cAMP), GHRP-2 via the ghrelin receptor (Gq/PLC/Ca²⁺) — different signaling pathways that explain synergy in combination and differential ACTH stimulation (only GHRP-2). For diagnostics, GHRP-2 is advantageous because of the additional ACTH marker; for therapy, Sermorelin would be safer due to the absence of cortisol stimulation and its FDA approval. Combining both offers maximum sensitivity for GHD diagnostics.

GHRP-2 vs. Ipamorelin

Ipamorelin (pentapeptide) also acts at GHS-R1a but is more selective: no ACTH/cortisol release. This makes it more popular in the off-label peptide scene; however, the body of human clinical studies is considerably thinner than for GHRP-2, which has a more robust evidence base in diagnostics and muscle protection.

Funding & Regulatory Disclaimer

Conclusion

GHRP-2 (Pralmorelin) is one of the best-characterized GH secretagogues. As a synthetic ghrelin receptor agonist, it stimulates pulsatile GH release via a signaling pathway independent of GHRH (Gq/PLC/Ca²⁺) — and it is precisely this duality that makes it the ideal partner for combined stimulation tests with maximum sensitivity for GH deficiency diagnostics.

The clinical evidence is robust in diagnostics: The GHRP-2 test is safe, fast (under 60 minutes), without hypoglycemia risk, and validated in both children and adults. ACTH measurement extends the test to a combined screening instrument for GH deficiency and adrenal insufficiency (PMID 35795807). Validation in children with a cut-off of 15 µg/L (PMID 20662346) provides a safe alternative to the ITT.

Beyond diagnostics, GHRP-2 shows promising therapeutic properties: muscle protection through suppression of the ubiquitin-proteasome axis (PMID 19577604), appetite stimulation (PMID 15699539), and modulation of visceral fat metabolism parameters (PMID 19351723). Clinical translation into Phase 2/3 trials, however, remains pending.

The safety profile is favorable compared to exogenous rhGH — pulsatile release under feedback control reduces supra-therapeutic levels. ACTH/cortisol stimulation and potential insulin resistance (PMID 28400207) require monitoring. Long-term data on cancer incidence are lacking — a research gap for the entire GHS class.

In the peptide landscape of 2026, GHRP-2 remains the best-validated ghrelin receptor agonist for endocrine diagnostics. Ipamorelin offers a more selective profile, Sermorelin offers FDA approval, Ibutamoren offers oral bioavailability — but no alternative achieves the same combination of diagnostic validation, pleiotropic breadth of action, and translational evidence. The message for patients remains: Do not self-administer research-grade GHRP-2 — diagnostic use belongs in the hands of endocrinologists, and therapeutic use remains experimental.